Form 4: Vertex Pharmaceuticals EVP Tatsis Sells Shares Under 10b5-1 Trading Plan

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold 2,175 shares of common stock at $460 per share on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Ourania Tatsis, an Executive Vice President and Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, sold 2,175 shares of common stock on June 3, 2024.
• The sale was executed at a price of $460 per share.
• The transaction was conducted under a pre-arranged trading plan pursuant to Rule 10b5-1, which was established on February 29, 2024.
• Following the transaction, Ms. Tatsis directly owns 49,098 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged trading plan. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Sales by company insiders are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates